BOSTON, May 3 – Harvard’s Institute of Proteomics will seek to raise $100 million from private and public sources in a bid to develop a repository of full-length cDNA clones that would assist researchers in their efforts to study proteins, Joshua LaBaer, the director of the institute, said Thursday.

“Celera and a number of other companies are planning to do proteomics profiling. We’re looking to be able to produce proteins rather than study them,” said LaBaer following a talk at the Whitehead Institute for Biomedical Research. “We’d like to give everybody access to the clones.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.